Tocilizumab: the first interleukin-6-receptor inhibitor (Q37226317)

19 August 2017

1 reference

title

Tocilizumab: the first interleukin-6-receptor inhibitor (English)

1 reference

19 August 2017

0 references

1 reference

Anthony Sebba

1

1 reference

19 August 2017

1 August 2008

1 reference

American Journal of Health-System Pharmacy

19 August 2017

1 reference

19 August 2017

65

1 reference

19 August 2017

1413-1418

1 reference

19 August 2017

15

1 reference

Genetics of rheumatoid arthritis

19 August 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Fatigue in rheumatoid arthritis reflects pain, not disease activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Inflammation: a pivotal link between autoimmune diseases and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Treatment of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Use of biologics in rheumatoid arthritis: where are we going?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Evolving concepts of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

The paradigm of IL-6: from basic science to medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

The pathophysiologic roles of interleukin-6 in human disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Signaling mechanisms through gp130: a model of the cytokine system.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Interleukin 6 and its receptor: ten years later

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Biological response modifiers in the management of rheumatoid arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Interleukin-6-deficient mice develop mature-onset obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

Interleukin-6: a new therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070449

31 March 2020

Identifiers

DOI

10.2146/AJHP070449

1 reference

19 August 2017

1 reference

PubMed ID

18653811